Septodont acquires injectable dental anesthetic manufacturing plant from Dentsply International
Septodont announces its acquisition of DLA, an injectable dental anesthetic manufacturing plant located in Brazil, from Dentsply International.
Septodont announced today that it has acquired DLA, an injectable dental anesthetic manufacturing plant, from Dentsply International. The plant is located in Catanduva, São Paulo, Brazil, and the acquisition was done through Septodont’s Brazilian affiliate, TDV.
Septodont currently owns manufacturing plants in Brazil, France, the United States, Canada, and India. Annually, Septodont produces more than 500 million dental injectable anesthetic cartridges, which are distributed to dental professionals in more than 150 countries. DLA produces injectable dental anestheticsunder the brands of Lidostesim (lidocaine), Mepivalem (mepivacaine), and Citanest (prilocaine).
“Our immediate goal is to provide all customers with a seamless integration period, meaning that things will remain business as usual for now,” said Paul Mondock, president of Septodont, Americas. “In the longer term, we will invest in the [Catanduva] site by upgrading the product offerings and capitalizing on the wonderful team that’s been established [there].”
This acquisition is Septodont's second in the Brazilian market. In 2014, Septodont acquired TDV, which is based in Pomerode, Santa Caterina, Brazil. With this new investment in DLA, the company plans to strengthen its presence throughout the Latin American region and beyond.
“Brazil is obviously a growth market for Septodont. We are very excited and proud to be the new owners of such a fantastic facility and look forward to the many opportunities that this plant will provide us, not only in Brazil but globally,” said Olivier Schiller, CEO of Septodont.